NOTES: PRESCREENING IS REQUIRED with clean, product-free face.
This study is using a color/shade scale. Only one panelist is needed for each shade type. At Pre Screening and at Pick Up measurements will be taken to ensure the specific shade is available. If a shade is already taken, subject cannot be on the study and there is no compensation.
Please read Full Inclusion and Exclusion Criteria below carefully.
Study Hours: 8 a.m. to 3:30 p.m.
Visit 1: Pick-up & Baseline – Monday, 6/27 – 1 hour
Visit 2: Day 28 – Monday, 7/25 – 15 minutes
Visit 1: Pick-up & Baseline – Wednesday, 7/6 – 1 hour
Visit 2: Day 28 – Wednesday, 8/3 – 15 minutes
a) Subject is female between 18-70 years of age;
b) Subject has Fitzpatrick skin type IV-VI (Note: Fitz VI is filled.)
c) Subjects have sensitive skin (11 subjects) or normal non-sensitive skin (16 subjects)
d) Subject agrees to use provided facial serum in place of their current facial moisturizer/serum.
e) Subject agrees not to introduce any new cosmetic or toiletry products during the study;
f) Subject is dependable and able to follow directions as outlined in the protocol and anticipates being available for all study visits;
g) Subject is willing to participate in all study evaluations;
h) Subject is in generally good health and has a current Panelist Profile Form on file at CRL;
i) Subject has completed a HIPAA Authorization Form in conformance with
45 CFR Parts 160 and 164;
j) Subject understands and is willing to sign an Informed Consent Form in conformance with 21 CFR Part 50: “Protection of Human Subjects”;
a) Subject is pregnant, nursing, planning a pregnancy, or not using adequate birth control;
b) Subject has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within two weeks prior to initiation of the study;
c) Subject has any cutaneous pathologies on the face (eczema, etc.)
d) Subject has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs;
e) Subject exhibits any rashes, scratches, or burn marks on the test site (face);
f) Subject has a history of skin cancer, or is currently undergoing treatment for active cancer of any kind;
g) Subject has diabetes;
h) Subject has a history of acute or chronic dermatologic, medical, and/or physical conditions which would, in the opinion of the Principal Investigator, preclude application of the test material and/or could influence the outcome of the study;
i) Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study